摘要
Background: COVID-19 was initially described to affect the respiratory system, it is now known to affect other systems and present in a myriad of ways. This has often proved to be a diagnostic and therapeutic challenge to clinicians and stretched healthcare resources, sometimes with poor outcomes. We report on an atypical presentation of SARS-CoV-2 infection as an acute exacerbation of myasthenia gravis in a low resource setting. Case Presentation: A middle aged male with myasthenia gravis presented with a three weeks’ history of worsening generalized weakness and three days’ history of new-onset dysphagia with no history of fever and cough. After a few days of apparent improvement, the patient developed progressive respiratory distress. Further evaluation confirmed bilateral pneumonia and COVID-19. Conclusion: There is a need for clinicians and health service providers to have a low threshold for suspicion and testing for COVID-19 in patients with pre-existing medical conditions and immunomodulatory therapy such as Myasthenia gravis.
Background: COVID-19 was initially described to affect the respiratory system, it is now known to affect other systems and present in a myriad of ways. This has often proved to be a diagnostic and therapeutic challenge to clinicians and stretched healthcare resources, sometimes with poor outcomes. We report on an atypical presentation of SARS-CoV-2 infection as an acute exacerbation of myasthenia gravis in a low resource setting. Case Presentation: A middle aged male with myasthenia gravis presented with a three weeks’ history of worsening generalized weakness and three days’ history of new-onset dysphagia with no history of fever and cough. After a few days of apparent improvement, the patient developed progressive respiratory distress. Further evaluation confirmed bilateral pneumonia and COVID-19. Conclusion: There is a need for clinicians and health service providers to have a low threshold for suspicion and testing for COVID-19 in patients with pre-existing medical conditions and immunomodulatory therapy such as Myasthenia gravis.
作者
Folajimi M. Otubogun
Adegoke M. Fatunwase
Olaniyi M. Fowosola
Khadijat M. Alli
Ojuolape O. Okedara
Bamidele S. Osalusi
Folajimi M. Otubogun;Adegoke M. Fatunwase;Olaniyi M. Fowosola;Khadijat M. Alli;Ojuolape O. Okedara;Bamidele S. Osalusi(Department of Medicine, Federal Medical Centre, Lagos, Nigeria;Department of Internal Medicine, Faculty of Clinical Sciences, University of Medical Sciences, Ondo, Nigeria;Department of Internal Medicine, Olabisi Onabanjo University Teaching Hospital, Sagamu, Nigeria;Department of Internal Medicine, Faculty of Clinical Sciences, Olabisi Onabanjo University, Ago-Iwoye, Nigeria)
